MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner

BOSTON–(BUSINESS WIRE)–MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced that Brian Shuster will join the Company as Entrepreneur Partner. Brian currently serves as Chief Business Officer of MPM BioImpact portfolio company Orna Therapeutics. “We are delighted to welcome Brian, a tenured biotechnology executive and expert in strategic business development, to MPM BioImpact. With
Read More

NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes, LLC and YAP Therapeutics, Inc. have entered into a collaboration agreement to develop and produce radiopharmaceuticals aimed at treating cancer and other chronic diseases. NorthStar is involved in the development, production, and commercialization of radiopharmaceuticals for therapeutic applications and medical imaging. YAP Therapeutics, a Fjord Ventures company, utilizes its advanced biologic and regenerativ
Read More

Horizon Technology Finance Provides $35 Million Venture Loan Facility to Onkos Surgical® to Accelerate Commercialization of Novel Antibacterial Implant Technology

FARMINGTON, Conn.–(BUSINESS WIRE)–Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to Onkos Surgical (“Onkos”), of which $30 million h
Read More

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development a
Read More

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Interventional Oncology (SIO) 2025 and Society of Surgical Oncology (SSO) 20
Read More

Emerging Clinical-Stage Neuroscience Company Nuvie Bio Announces Positive Phase 1 Data with its Lead Migraine Program

SAN DIEGO–(BUSINESS WIRE)–Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a first-in-human trial with NVI-100, the company’s lead investigational drug for the acute treatment of migraine. NVI-100 is a first-in-class water-soluble peptide antagonist for the calcitonin gene-related peptide (CGRP) receptor delivered via a patient-friendly autoinjector for
Read More

AI Proteins Enters into Collaborative Research Agreement with the University of Missouri on Radioligand Therapy

BOSTON–(BUSINESS WIRE)–AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement with the University of Missouri-Columbia to work with Dr. Carolyn Anderson, Simón-Ellebracht Professor in Medicinal Chemistry and Professor of Radiology, and her team to jointly pursue specific research projects to advance the use of de novo designed miniproteins for targe
Read More

Ontrak Health Announces New Customer Partnership with Intermountain Health to Deliver Value-Based Behavioral Health Services to Medicare Advantage Members

MIAMI–(BUSINESS WIRE)–Ontrak, Inc (NASDAQ: OTRK), (“Ontrak” or the “Company”), an AI-powered and telehealth-enabled behavioral healthcare company, announced it has signed an agreement to provide its behavioral health solutions to Intermountain Health’s Medicare Advantage members in Nevada. Intermountain Health is a prominent healthcare system operating 400 clinics and 34 hospitals in the western United States. Intermountain Health is known for its high quality, affordable and personalized car
Read More
Top